Get the Stockscreener App
0.4575
30.08%
0.1058
Medicus Pharma Ltd stock is traded at $0.4575, with a volume of 11.60M.
It is up +30.08% in the last 24 hours and up +57.16% over the past month.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.
See More
Previous Close:
$0.3517
Open:
$0.3636
24h Volume:
11.60M
Relative Volume:
3.14
Market Cap:
$25.92M
Revenue:
-
Net Income/Loss:
$-28.53M
P/E Ratio:
-0.257
EPS:
-1.7805
Net Cash Flow:
$-20.10M
1W Performance:
+37.47%
1M Performance:
+57.16%
6M Performance:
-72.44%
1Y Performance:
-82.27%
1-Day Range:
$0.3636
$0.476
1-Week Range:
$0.32
$0.476
52-Week Range:
$0.25
$3.69
Medicus Pharma Ltd Stock (MDCX) Company Profile
Name
Medicus Pharma Ltd
Sector
Industry
Phone
610-540-7515
Address
300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN
Compare MDCX vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDCX
Medicus Pharma Ltd
|
0.4575 | 25.92M | 0 | -28.53M | -20.10M | -1.7805 |
LLY
Lilly Eli Co
|
1,098.57 | 979.64B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
228.39 | 549.78B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
216.49 | 382.49B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
113.87 | 281.24B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
147.08 | 280.64B | 54.66B | 13.58B | 16.05B | 7.0171 |
Medicus Pharma Ltd Stock (MDCX) Latest News
Medicus Pharma Ltd (MDCXW) Institutional Confidence - TradingKey
Medicus Pharma Ltd (MDCXW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Medicus Pharma Ltd (MDCXW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Medicus Pharma Ltd (MDCXW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Medicus Pharma Ltd (MDCXW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Medicus Pharma Ltd (MDCX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Medicus Pharma Ltd (MDCX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Medicus Pharma Ltd (MDCX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Medicus Pharma Ltd (MDCX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Medicus Pharma Ltd (MDCX) Institutional Confidence - TradingKey
Medicus Pharma Ltd (MDCX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Medicus Pharma Ltd (MDCX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform - Montgomery Advertiser
This $9 SpaceX Stock Has Crazy Potential Geena Davis (jBXkEb6qgn) - Mshale
This $9 SpaceX Stock Has Crazy Potential Ottawa News (6IhxvTriSq) - Fathom Journal
Medicus Pharma Ltd (MDCXW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Medicus Pharma Ltd. (MDCX) has officially submitted an application to the United States Food and Drug Administration (FDA) seeking Rare Pediatric Disease Designation for its investigational product Skinject® for the indication of Gorlin syndrome. - Bitget
Medicus advances Teverelix development with EU Phase 2b trial submission in Prostate Cancer - Proactive financial news
Medicus advances Teverelix and SkinJect programs with key regulatory filings - Proactive Investors
Small cap wrap: Medicus Pharma, First Phosphate, Standard Uranium... - Proactive financial news
Medicus Dips on FDA Nod - Baystreet.ca
Medicus Pharma seeks rare pediatric disease tag for SkinJect in Gorlin Syndrome - Proactive financial news
Medicus Pharma seeks rare pediatric disease status for patch - Investing.com
Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome - The Manila Times
Medicus Pharma seeks rare pediatric disease status for patch By Investing.com - Investing.com UK
Medicus Pharma Announces U.S. Food and Drug Administration - GlobeNewswire
Medicus Pharma files for RPDD for SkinJect in gorlin syndrome - grafa.com
MDCX Stock Price, Quote & Chart - ChartMill
Medicus Pharma on Bloomberg World - South Bend Tribune
MDCX News | MEDICUS PHARMA LTD (NASDAQ:MDCX) - ChartMill
Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony - South Bend Tribune
Medicus Pharma (NASDAQ:MDCX) Share Price | RNS News, Quotes, & Charts | MDCX | - Proactive Investors
Small cap wrap: Fineqia, Phunware, Medicus Pharma... - Proactive financial news
Medicus Pharma Submits Ind Application for PRECISION-E2 Phase 2A Study of Teverelix in Endometriosis in United Arab Emirates - marketscreener.com
Medicus Pharma files IND for genomics-enabled endometriosis trial in UAE - Yahoo! Finance Canada
Medicus Pharma submits IND application for endometriosis trial By Investing.com - Investing.com Australia
Medicus Pharma submits IND application for endometriosis trial - Investing.com
Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program - The Manila Times
Medicus Pharma Ltd. Submits IND Application for Innovative PRECISION-E2 Phase 2a Clinical Trial in Endometriosis - Quiver Quantitative
UAE study uses Emirati genome data to tailor endometriosis treatment - Stock Titan
Medicus Pharma submits endometriosis IND in Abu Dhabi - grafa.com
MDCX Q1 2026 Earnings: EPS Miss as Losses Deepen, Stock DeclinesRevenue Growth Outlook - newsline.com
ICYMI: Medicus Advances SkinJect Into Registrational Study for Rare Disorder - MyChesCo
Small cap wrap: Grey Matters Health, Medicus Pharma, ReconAfrica, EnWave... - Proactive financial news
Medicus submits EU filing for Teverelix prostate cancer study - Investing.com UK
Medicus Pharma submits EU clinical trial modification for prostate cancer drug Teverelix - Yahoo Finance
Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission - The Manila Times
Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High ... - Caledonian Record
Medicus Pharma Advances Teverelix® Program Towards - GlobeNewswire
Medicus Pharma advances SkinJect for Gorlin syndrome – ICYMI - Proactive financial news
Medicus Pharma reports dose response data from skin cancer study - Investing.com
Medicus Pharma Ltd Stock (MDCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):